|
MKK3/MYC Protein-Protein Interaction Inhibitor Overcomes Resistant Non-Small Cell Lung Cancer
Application
A therapeutic use for SGI-1027 in the treatment of Osimertinib-resistant non-small cell lung cancer (NSCLC).
Key Benefits
The MKK3/MYC protein-protein interaction inhibitor SGI-1027 effectively decreases MYC levels in Osimertinib-resistant NSCLC cell lines.
The combination of SGI-1027 with Osimertinib offers synergistic benefits over...
Published: 10/3/2025
Contributor(s): Andrey Ivanov, Haian Fu, Shi-Yong Sun, Zhen Chen
|
